119 related articles for article (PubMed ID: 17536882)
1. Efficacy of UFT plus Tamoxifen for Estrogen-Receptor-Positive Breast Cancer and Tamoxifen plus UFT for Estrogen-Receptor-Negative Breast Cancer : Adjuvant Therapy after Administration of Mitomycin.
Ogita M; Uchino J; Asaishi K; Kubo Y; Tanabe T; Hata A; Hirata K; Mito M;
Clin Drug Investig; 2003; 23(11):689-99. PubMed ID: 17536882
[TBL] [Abstract][Full Text] [Related]
2. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
[TBL] [Abstract][Full Text] [Related]
3. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
4. UFT and mitomycin plus tamoxifen for stage II, ER-positive breast cancer. Hokkaido ACETBC Study Group.
Hata Y; Uchino J; Asaishi K; Kubo Y; Mito M; Tanabe T; Ogita M; Hirata K
Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):91-5. PubMed ID: 10442372
[TBL] [Abstract][Full Text] [Related]
5. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
6. Postoperative adjuvant randomised trial comparing chemoendocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) of Japan.
Morimoto T; Ogawa M; Orita K; Sugimachi K; Toge T; Dohi K; Nomura Y; Monden Y; Ogawa N
Eur J Cancer; 1996 Feb; 32A(2):235-42. PubMed ID: 8664034
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.
Li L; Chang B; Jiang X; Fan X; Li Y; Li T; Wu S; Zhang J; Kariminia S; Li Q
BMC Cancer; 2018 Oct; 18(1):977. PubMed ID: 30314452
[TBL] [Abstract][Full Text] [Related]
8. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.
Toi M; Hattori T; Akagi M; Inokuchi K; Orita K; Sugimachi K; Dohi K; Nomura Y; Monden Y; Hamada Y
Cancer; 1992 Nov; 70(10):2475-83. PubMed ID: 1423177
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer stratified by estrogen receptors.
Nomura Y; Tashiro H; Hisamatsu K; Shinozuka K
Cancer; 1988 Jun; 61(11):2168-75. PubMed ID: 3130175
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of postoperative adjuvant therapy for stage ilia breast cancer: Futraful vs futraful+tamoxifen for ER-positive patients and futraful vs futraful + adriamycin for ER-negative breast cancer.
Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
Breast Cancer; 1997; 4(2):103-13. PubMed ID: 18843555
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Post-operative Adjuvant Therapy for Stage IIIa Berast Cancer: Futraful vs Futraful+Tamoxifen for ER-positive Patients and Futraful vs Futraful+Adriamycin for ER-negative Breast Cancer.
Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sakai K; Koyama H; Sugimachi K; Nomura Y; Hattori T; Ogawa N
Breast Cancer; 1997 Jul; 4(2):103-113. PubMed ID: 11091584
[TBL] [Abstract][Full Text] [Related]
12. [A comparative study among ftorafur, ftorafur plus tamoxifen, and tamoxifen in adjuvant therapy for breast cancer. The Chubu Cooperative Study Group of Adjuvant Chemoendocrine Therapy for Breast Cancer, Japan].
Yoshida M; Saji S; Takagi H; Takeuchi S; Tsuda H; Nimura Y; Mizumoto R; Miyazaki I; Kobayashi S; Noguchi M
Gan To Kagaku Ryoho; 1993 Dec; 20(15):2325-33. PubMed ID: 8259846
[TBL] [Abstract][Full Text] [Related]
13. Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy.
Toi M; Ikeda T; Akiyama F; Kurosumi M; Tsuda H; Sakamoto G; Abe O
Int J Oncol; 2007 Oct; 31(4):899-906. PubMed ID: 17786323
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase III trial of adjuvant chemotherapy with oral uracil and tegafur plus leucovorin versus intravenous fluorouracil and levofolinate in patients with stage III colorectal cancer who have undergone Japanese D2/D3 lymph node dissection: final results of JCOG0205.
Shimada Y; Hamaguchi T; Mizusawa J; Saito N; Kanemitsu Y; Takiguchi N; Ohue M; Kato T; Takii Y; Sato T; Tomita N; Yamaguchi S; Akaike M; Mishima H; Kubo Y; Nakamura K; Fukuda H; Moriya Y
Eur J Cancer; 2014 Sep; 50(13):2231-40. PubMed ID: 24958736
[TBL] [Abstract][Full Text] [Related]
15. [Experimental combined chemo- and endocrine therapy with UFT and tamoxifen in human breast carcinoma xenografts serially transplanted into nude mice].
Kubota T; Josui K; Ishibiki K; Abe O; Yamada Y; Asanuma F; Kawamura E; Koh J; Shiina E
Nihon Gan Chiryo Gakkai Shi; 1990 Dec; 25(12):2767-73. PubMed ID: 2074386
[TBL] [Abstract][Full Text] [Related]
16. Addition of adjuvant tamoxifen to cyclophosphamide, methotrexate and 5-fluorouracil for premenopausal women with oestrogen receptor-positive breast cancer.
Li HC; Wen XF; Hou YF; Shen KW; Wu J; Lu JS; Shen ZZ; Shao ZM
Asian J Surg; 2003 Jul; 26(3):163-8. PubMed ID: 12925292
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52.
Ingle JN; Suman VJ; Mailliard JA; Kugler JW; Krook JE; Michalak JC; Pisansky TM; Wold LE; Donohue JH; Goetz MP; Perez EA
Breast Cancer Res Treat; 2006 Jul; 98(2):217-22. PubMed ID: 16538529
[TBL] [Abstract][Full Text] [Related]
18. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
Nomura Y; Tsutsui S; Murakami S; Takenaka Y
Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
[TBL] [Abstract][Full Text] [Related]
19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
[TBL] [Abstract][Full Text] [Related]
20. Ten-year results of a randomized trial on adjuvant chemo-endocrine therapy with tamoxifen for stage II breast cancer.
Hata Y; Takahashi H; Todo S; Okazaki M; Asaishi K; Hirata K; Okushiba S; Kato H; Uchino J
Breast Cancer; 2003; 10(2):134-9. PubMed ID: 12736566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
